Ophthalmic clinical trials

Full inclusion and exclusion criteria can be found on VANTAGE.

Trial details

• Daily oral tablet of VX-01 (inhibitor of AOC-3) vs oral placebo (randomised 1:1) for NPDR (non-CI)
• All patients will take 1 tablet of VX-01 or placebo twice a day for 52 weeks
• Study duration up to 52 weeks.

Full inclusion and exclusion criteria can be found at KLARITY.

• An intravitreal injection (IVT) of KIO-104, an active pharmaceutical ingredient (API)
• Cohort 1: IVT of 3.5 µg KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Cohort 2: IVT injection of 10 µg8 KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Study duration up to 20 weeks

Full inclusion and exclusion criteria can be found at BIOCRYST.   

• A single Suprachoroidal injection (SCh) of BCX4161
• Cohort 1: Low dose of BCX4161 via SCh injection
• Cohort 2: Medium dose of BCX4161 via SCh injection
• Cohort 3: High dose of BCX4161 via SCh injection
• Study duration up to 24 weeks

Full inclusion and exclusion criteria can be found at THERINI.

• 3x IVT injections of THN391in multiple ascending doses
• Cohort 1: 1.2 mg THN391 IVT every 4 weeks
• Cohort 2: 3.5 mg THN391 IVT every 4 weeks
• Cohort 3: 10.0 mg THN391 IVT every 4 weeks
• Study duration up to 20 weeks

Full inclusion and exclusion criteria can be found at BENOBIO.

Trial details

• Single intravitreal injection of BBC1501 (BET inhibitor)
• Study duration up to 12 weeks.
• 3 ascending dosing cohorts, 1.25μg, 2.5μg, 5μg
• Primary objective: safety and tolerability

Full inclusion and exclusion criteria can be found at KLARITY.

• An intravitreal injection (IVT) of KIO-104, an active pharmaceutical ingredient (API)
• Cohort 1: IVT of 3.5 µg KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Cohort 2: IVT injection of 10 µg8 KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Study duration up to 20 weeks

Full inclusion and exclusion criteria can be found at KLARITY.

• An intravitreal injection (IVT) of KIO-104, an active pharmaceutical ingredient (API)
• Cohort 1: IVT of 3.5 µg KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Cohort 2: IVT injection of 10 µg8 KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Study duration up to 20 weeks

Full inclusion and exclusion criteria can be found at iSight-2.

• A Microcurrent Stimulation (MCS) therapy for intermediate to advanced nonexudative (dry) AMD
• Randomised into 2 Active: 1 Sham
• Study Duration 14 months

Full inclusion and exclusion criteria can be found at MYRTLE.

Trial details

• Single and multiple intravitreal ascending dose of PYC-001, a peptidephosphorodiamidate morpholino oligonucleotide (PPMO)
  • Single Dose Cohort:  Single 60 μg dose
  • Repeat Dose Cohorts: Repeat dose:
    • Cohort 1: 10 μg (low dose)
    • Cohort 2: 30 μg (medium dose)
    • Cohort 3: 60 μg (high dose)
• And two dosing regimens:
  • Group A: Once every 8 weeks
  • Group B: Once every 12 weeks
• Study duration up to 60 weeks
• Primary objective, safety and tolerability

More details can be found on the MacTel Registry page. 

Trial details

• Registry study
• Blood sample and data collection
• New or existing patients to the hospital
• Single visit

Full inclusion and exclusion criteria can be found at KLARITY.

• An intravitreal injection (IVT) of KIO-104, an active pharmaceutical ingredient (API)
• Cohort 1: IVT of 3.5 µg KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Cohort 2: IVT injection of 10 µg8 KIO-104 administered in the study eye every 2 weeks, for up to 3 consecutive doses
• Study duration up to 20 weeks

Full inclusion and exclusion criteria can be found at HYPERION

• Double masked randomised, placebo-controlled, paired eye intravitreal injection of Sepofarsen
• Injected every 6 months
• Study duration up to 24 months
• Evaluate the efficacy, safety and tolerability of Sepofarsen

Full inclusion and exclusion criteria can be found at STAR-MOG

• All ages with first presentation of suspected clinical phenotype for MOGAD
• Study duration up to 12 months
• Evaluate efficacy of optimised corticosteroid tearing regime vs placebo